Trillium Therapeutics Provides Additional Details on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
273
Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

TORONTO, ONTARIO--(Marketwired - Feb. 24, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented new pharmacology data from its ongoing Phase 1 a/b trial of TTI-621, a SIRPaFc fusion protein targeting CD47 in patients with advanced hematologic malignancies. The presentation took place at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

The company presented the following new information from the trial:

Receptor occupancy increases with multiple infusions of TTI-621, conferring robust CD47 blockade on circulating leukemic cells: Compared to the initial infusion, the extent and duration of CD47 occupancy on peripheral leukocytes was elevated following the sixth dose. Importantly, emerging data suggests increased receptor occupancy on circulating leukemic blast cells. The level of target engagement achieved is associated with strong phagocytosis activity of tumor cells in vitro.

Increases in cytokines associated with macrophage activation suggest rapid engagement of the innate immune system: Post-infusion elevations were observed in MIP-1a, MIP-1b and other cytokines associated with macrophage activation, supporting the proposed role of TTI-621 as an innate immune checkpoint inhibitor.

Transient thrombocytopenia due to target mediated clearance is attenuated subsequent to the first infusion of TTI-621: Additional data has clarified that the transient thrombocytopenia observed following TTI-621 exposure is often diminished after multiple infusions. This suggests that there may be an opportunity to increase TTI-621 exposure in patients after the initial dose.

Weekly infusions lead to a longer half-life and accumulation of circulating drug, overcoming the platelet antigen sink: After six infusions the terminal half-life of TTI-621 increased to 3.7 days with an attendant rise in circulating drug trough levels, which is consistent with the half-lives of many marketed Fc fusion proteins. Drug accumulation was accompanied by stable pre-dose platelet counts, suggesting that multiple infusions of TTI-621 overcome the platelet antigen sink.

"This recently expanded data set markedly advances our understanding of TTI-621's pharmacological properties, and exemplifies the emerging nature of this exciting development program," said Dr. Niclas Stiernholm, Trillium's Chief Executive Officer. "These latest results suggest that we overcome the antigen sink and achieve meaningful TTI-621 exposure while maintaining acceptable platelet counts. We are excited to continue the exploration of this unique checkpoint inhibitor in patients with multiple types of blood cancers, as well as in patients with solid tumors."

The ASCO-SITC poster presentation on TTI-621 can be found on the company's website at www.trilliumtherapeutics.com . Additional information about this clinical trial of TTI-621 is available at www.clinicaltrials.gov using identifier: NCT02663518.

About Trillium Therapeutics

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase 1 clinical trial ( NCT02663518 ) evaluating SIRPaFc is ongoing in advanced hematologic malignancies, and a second Phase 1 trial is underway in solid tumors ( NCT02890368 ). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information

This press release may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties, including our expectations about overcoming the antigen sink and having drug concentrations associated with biological activity, and the longer terminal serum half-life of the drug and increased target receptor occupancy and attenuated decreases in platelets with repeated dosing, are described in the Company's ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Trillium Therapeutics Inc. James Parsons Chief Financial Officer 416-595-0627 x232 james@trilliumtherapeutics.com www.trilliumtherapeutics.com Investor and Media Relations: Canale Communications for Trillium Therapeutics Mark Corbae 619-849-5375 mark@canalecomm.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cinmoore's Smart Camera: A Game Changer for Car Security

Updated Category News Views 96

Pioneering Car Security with Cinmoore's Smart Camera Ever left your car in the parking lot, heart pounding, wondering if it's safe while you run errands? Well, Cinmoore might just quell that parking paranoia with their new gizmo, the Smart Parking Camera DC1U. This device isn't just some fancily-packaged disappointment—it promises some serious peace of mind for those...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 94

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 55

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 142

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 98

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 86

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 25

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 73

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Trump's Tariff Threats Spark Global Market Reactions

Updated Category News Views 163

Market Reactions to Tariff Developments As global markets navigate uncertain waters today, optimism and anxiety intertwine. The US dollar has taken a slight step higher, while gold has seen a dip, all stemming from ongoing trade tensions and recent tariff announcements by President Trump. With negotiations that are seen as promising but fraught with complexities, the...

Continue Reading
Sutro Biopharma's Upcoming Presentation at J.P. Morgan Event

Updated Category News Views 228

Sutro Biopharma's Upcoming Conference Presentation Sutro Biopharma, Inc. (NASDAQ: STRO), a trailblazer in oncology therapies based in South San Francisco, has some exciting news. The company announced that its Chief Executive Officer, Bill Newell, will be presenting at the prestigious J.P. Morgan Healthcare Conference. This annual event is a pivotal opportunity for...

Continue Reading
Nightly Launches Ambitious $25 Million Experience Initiative

Updated Category News Views 302

Nightly Introduces a $25 Million Initiative In a bold move to reshape the live entertainment landscape, Nightly has announced a substantial $25 million initiative aimed at expanding its dynamic experiences across the nation. Originating from Dallas, Nightly has quickly evolved into a cultural movement that seeks to redefine nightlife specifically for Gen Z audiences. This...

Continue Reading
Tecan Announces 2024 Results, Focuses on Growth and Innovation

Updated Category News Views 609

Tecan Reports 2024 Financial Results Amid Market Challenges Overview of Financial Highlights Tecan has unveiled its financial results for 2024, showcasing a robust commitment to enhancing operational resilience in a challenging market environment. Sales figures totaled CHF 934.3 million, marking a decline from the previous year's CHF 1,074.4 million. This 13.0% drop in...

Continue Reading
Auddia, Inc. (AUUD) Merger: Shareholder Alert and Investigation Insights

Updated Category News Views 227

Auddia, Inc. (NASDAQ: AUUD) is under the microscope after news broke about its proposed merger with McCarthy Finney, Inc., which sent shockwaves through trader desks and shareholder circles alike. The date was February 18, 2026, when class action attorney Juan Monteverde announced an investigation into the deal that’s left many scratching their heads about whether this...

Continue Reading